Search

Your search keyword '"Gockerman, Jon P."' showing total 382 results
Start Over Author "Gockerman, Jon P."
382 results on '"Gockerman, Jon P."'

1. Data from A Genomic Approach to Improve Prognosis and Predict Therapeutic Response in Chronic Lymphocytic Leukemia

Author

Friedman, Daphne R., primary, Weinberg, J. Brice, primary, Barry, William T., primary, Goodman, Barbara K., primary, Volkheimer, Alicia D., primary, Bond, Karen M., primary, Chen, Youwei, primary, Jiang, Ning, primary, Moore, Joseph O., primary, Gockerman, Jon P., primary, Diehl, Louis F., primary, Decastro, Carlos M., primary, Potti, Anil, primary, and Nevins, Joseph R., primary

Published
2023
Full Text
View/download PDF

2. Supplemental Figure 1 from Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study

Author

Horn, Leora, primary, Infante, Jeffrey R., primary, Reckamp, Karen L., primary, Blumenschein, George R., primary, Leal, Ticiana A., primary, Waqar, Saiama N., primary, Gitlitz, Barbara J., primary, Sanborn, Rachel E., primary, Whisenant, Jennifer G., primary, Du, Liping, primary, Neal, Joel W., primary, Gockerman, Jon P., primary, Dukart, Gary, primary, Harrow, Kimberly, primary, Liang, Chris, primary, Gibbons, James J., primary, Holzhausen, Allison, primary, Lovly, Christine M., primary, and Wakelee, Heather A., primary

Published
2023
Full Text
View/download PDF

3. Supplemental Table 1 from Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study

Author

Horn, Leora, primary, Infante, Jeffrey R., primary, Reckamp, Karen L., primary, Blumenschein, George R., primary, Leal, Ticiana A., primary, Waqar, Saiama N., primary, Gitlitz, Barbara J., primary, Sanborn, Rachel E., primary, Whisenant, Jennifer G., primary, Du, Liping, primary, Neal, Joel W., primary, Gockerman, Jon P., primary, Dukart, Gary, primary, Harrow, Kimberly, primary, Liang, Chris, primary, Gibbons, James J., primary, Holzhausen, Allison, primary, Lovly, Christine M., primary, and Wakelee, Heather A., primary

Published
2023
Full Text
View/download PDF

4. Supplemental Table 2 from Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study

Author

Horn, Leora, primary, Infante, Jeffrey R., primary, Reckamp, Karen L., primary, Blumenschein, George R., primary, Leal, Ticiana A., primary, Waqar, Saiama N., primary, Gitlitz, Barbara J., primary, Sanborn, Rachel E., primary, Whisenant, Jennifer G., primary, Du, Liping, primary, Neal, Joel W., primary, Gockerman, Jon P., primary, Dukart, Gary, primary, Harrow, Kimberly, primary, Liang, Chris, primary, Gibbons, James J., primary, Holzhausen, Allison, primary, Lovly, Christine M., primary, and Wakelee, Heather A., primary

Published
2023
Full Text
View/download PDF

5. Supplementary Data from A Genomic Approach to Improve Prognosis and Predict Therapeutic Response in Chronic Lymphocytic Leukemia

Author

Friedman, Daphne R., primary, Weinberg, J. Brice, primary, Barry, William T., primary, Goodman, Barbara K., primary, Volkheimer, Alicia D., primary, Bond, Karen M., primary, Chen, Youwei, primary, Jiang, Ning, primary, Moore, Joseph O., primary, Gockerman, Jon P., primary, Diehl, Louis F., primary, Decastro, Carlos M., primary, Potti, Anil, primary, and Nevins, Joseph R., primary

Published
2023
Full Text
View/download PDF

6. Supplemental Table 3 from Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study

Author

Horn, Leora, primary, Infante, Jeffrey R., primary, Reckamp, Karen L., primary, Blumenschein, George R., primary, Leal, Ticiana A., primary, Waqar, Saiama N., primary, Gitlitz, Barbara J., primary, Sanborn, Rachel E., primary, Whisenant, Jennifer G., primary, Du, Liping, primary, Neal, Joel W., primary, Gockerman, Jon P., primary, Dukart, Gary, primary, Harrow, Kimberly, primary, Liang, Chris, primary, Gibbons, James J., primary, Holzhausen, Allison, primary, Lovly, Christine M., primary, and Wakelee, Heather A., primary

Published
2023
Full Text
View/download PDF

7. Supplemental Figure 2 from Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study

Author

Horn, Leora, primary, Infante, Jeffrey R., primary, Reckamp, Karen L., primary, Blumenschein, George R., primary, Leal, Ticiana A., primary, Waqar, Saiama N., primary, Gitlitz, Barbara J., primary, Sanborn, Rachel E., primary, Whisenant, Jennifer G., primary, Du, Liping, primary, Neal, Joel W., primary, Gockerman, Jon P., primary, Dukart, Gary, primary, Harrow, Kimberly, primary, Liang, Chris, primary, Gibbons, James J., primary, Holzhausen, Allison, primary, Lovly, Christine M., primary, and Wakelee, Heather A., primary

Published
2023
Full Text
View/download PDF

8. Supplemental Figure 3 from Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study

Author

Horn, Leora, primary, Infante, Jeffrey R., primary, Reckamp, Karen L., primary, Blumenschein, George R., primary, Leal, Ticiana A., primary, Waqar, Saiama N., primary, Gitlitz, Barbara J., primary, Sanborn, Rachel E., primary, Whisenant, Jennifer G., primary, Du, Liping, primary, Neal, Joel W., primary, Gockerman, Jon P., primary, Dukart, Gary, primary, Harrow, Kimberly, primary, Liang, Chris, primary, Gibbons, James J., primary, Holzhausen, Allison, primary, Lovly, Christine M., primary, and Wakelee, Heather A., primary

Published
2023
Full Text
View/download PDF

12. “Short Course” Bortezomib plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Nontransplant Candidates in Patients with Previously Untreated Multiple Myeloma

Author

Gasparetto, Cristina, Gockerman, Jon P., Diehl, Louis F., de Castro, Carlos M., Moore, Joseph O., Long, Gwynn D., Horwitz, Mitchell E., Keogh, George, Chute, John P., Sullivan, Keith M., Neuwirth, Rachel, Davis, Patricia H., Sutton, Linda M., Anderson, Russell D., Chao, Nelson J., and Rizzieri, David

Published
2010
Full Text
View/download PDF

24. Phase III Randomized Trial of Patient-Specific Vaccination for Previously Untreated Patients with Follicular Lymphoma in First Complete Remission: Protocol Summary and Interim Report

Author

Neelapu, Sattva S., Gause, Barry L., Nikcevich, Daniel A., Schuster, Stephen J., Winter, Jane, Gockerman, Jon P., Loughran, Thomas, Jr, Takeshita, Ken, Inghirami, Giorgio, McGaughey, Dean, Watson, Thelma M., Snow, Sandra, Kubovic, Paula, Ferraro, Miriam, Jones, Elizabeth, Jaffe, Elaine S., Schwartzentruber, Douglas J., Danforth, David, Sherry, Richard, Kass, Erik, Waes, Carter Van, Reynolds, Craig W., and Kwak, Larry W.

Published
2005

29. Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma

Author

Rizzieri, David A., Sand, Gregory J., McGaughey, Dean, Moore, Joseph O., DeCastro, Carlos, Chao, Nelson J., Vredenburgh, James J., Gasparetto, Cristina, Long, Gwynn D., Anderson, Elizabeth, Foster, Tracy, Toaso, Bonnie, Adams, Donna, Donna Niedzwiecki, and Gockerman, Jon P.

Subjects
Non-Hodgkin's lymphomas -- Drug therapy, Paclitaxel -- Dosage and administration, Paclitaxel -- Evaluation, Health
Published
2004

31. Barriers to the participation of African-American patients with cancer in clinical trials: a pilot study

Author

Advani, Anjali S., Atkeson, Benjamin, Brown, Carrie L., Peterson, Bercedis L., Fish, Laura, Johnson, Jeffrey L., Gockerman, Jon P., and Gautier, Marc

Subjects
Human experimentation in medicine -- Demographic aspects, Human experimentation in medicine -- Research, Oncology, Experimental -- Management, African Americans -- Health aspects, Company business management, Health
Published
2003

35. A pilot study of etoposide, vinblastine, and doxorubicin plus involved field irradiation in advanced, previously untreated Hodgkin's disease

Author

Brizel, David M., Gockerman, Jon P., Crawford, Jeffrey, Hathorn, James W., Moore, Joseph O., Osborne, Bernice, and Prosnitz, Leonard R.

Subjects
Etoposide -- Evaluation, Vinblastine -- Evaluation, Doxorubicin -- Evaluation, Hodgkin's disease -- Care and treatment, Radiotherapy -- Evaluation, Health
Abstract

Background. Advanced stage Hodgkin's disease (HD) usually is treated with combination chemotherapy with or without supplemental irradiation. The risk of significant acute and long term toxicity when the chemotherapy regimen contains alkylating agents has provided the impetus for the development of systemic combinations that do not include alkylating agents. This trial was designed to assess the toxicity and efficacy of a regimen of etoposide, vinblastine, and doxorubicin (EVA) as part of a combined modality approach in patients with moderate to high risk HD. Methods. This was a prospective pilot study that included 26 previously untreated patients. They received 6 cycles of EVA, and complete responders received low dose (1500-2500 cGy) involved field radiation. Results. Four patients were hospitalized for sepsis during chemotherapy. Complete response was achieved in 54% of patients, and 46% patients experienced induction failures. Two year failure-free survival is 44%, while 2 year overall survival is 86%. Median follow-up is 27 months. Conclusions. The EVA regimen is no more efficacious than other programs already in use and may be less so. It also is potentially leukemogenic because of the presence of etoposide. New combinations that do not contain etoposide should be explored in therapy programs for advanced HD in the hopes of discovering an efficacious treatment program that has minimal long term side effects.

Published
1994

36. The radiographic diagnosis and treatment of paraneoplastic central nervous system disease

Author

Glantz, Michael J., Biran, Haim, Myers, Mark E., Gockerman, Jon P., and Friedberg, Marc H.

Subjects
Nervous system cancer -- Care and treatment, Paraneoplastic syndromes -- Care and treatment, Health
Abstract

Paraneoplastic nervous system syndromes are being identified with increasing frequency because of greater physician awareness and the availability of serodiagnostic tests for some syndromes. Frequently, paraneoplastic syndromes develop in the setting of an indolent, limited stage, or otherwise occult malignancy. As a result, the paraneoplastic disorder often becomes the most disabling part of a patient's disease. Effective treatment appears to require early identification. For these reasons, the ability to diagnose a paraneoplastic syndrome, follow its course, and treat it successfully are important. The authors describe four patients with neurologic paraneoplastic syndromes and identical magnetic resonance imaging abnormalities. Three patients responded to immunosuppressive or immunomodulatory therapy, and in one, corresponding radiographic improvement was documented. Strategies for early diagnosis and options for treatment of paraneoplastic nervous system disorders are discussed.

Published
1994

38. Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study

Author

Horn, Leora, primary, Infante, Jeffrey R., additional, Reckamp, Karen L., additional, Blumenschein, George R., additional, Leal, Ticiana A., additional, Waqar, Saiama N., additional, Gitlitz, Barbara J., additional, Sanborn, Rachel E., additional, Whisenant, Jennifer G., additional, Du, Liping, additional, Neal, Joel W., additional, Gockerman, Jon P., additional, Dukart, Gary, additional, Harrow, Kimberly, additional, Liang, Chris, additional, Gibbons, James J., additional, Holzhausen, Allison, additional, Lovly, Christine M., additional, and Wakelee, Heather A., additional

Published
2018
Full Text
View/download PDF

39. MINI01.02: Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (pts) with ALK+ NSCLC

Author

Horn, Leora, primary, Wakelee, Heather, additional, Reckamp, Karen L., additional, Blumenschein, George, additional, Infante, Jeffrey R., additional, Carter, Corey A., additional, Waqar, Saiama N., additional, Neal, Joel W., additional, Harrow, Kimberly, additional, Gockerman, Jon P., additional, Dukart, Gary, additional, Liang, Chris, additional, Gibbons, James L., additional, Hernandez, Jennifer, additional, Newman-Eerkes, Tera, additional, Lim, Lee, additional, and Lovly, Christine M., additional

Published
2016
Full Text
View/download PDF

40. The use of prophylactic eye drops during high-dose cytosine arabinoside therapy

Author

Higa, Gerald M., Gockerman, Jon P., Hunt, Allison L., Jones, Mary Ruth, and Horne, Barbara J.

Subjects
Keratitis -- Prevention, Chemotherapy -- Adverse and side effects, Keratoconjunctivitis -- Prevention, Conjunctivitis -- Prevention, Cytarabine -- Adverse and side effects, Health
Abstract

Cytosine arabinoside, often abbreviated ara-C, is a powerful chemotherapeutic drug used in the treatment of some leukemias and other cancers. One of the side effects of ara-C is inflammation of the conjunctiva, which lines the eyelids, and inflammation of the cornea of the eye (called conjunctivitis and keratitis, respectively). When high doses of ara-C are used, as many as 85 percent of patients are likely to experience these reactions. Since the high doses are considered to be critical for the success of treatment, attempts have been made to mitigate these side effects. One treatment that has shown promise is the use of steroid drugs dissolved in eye drops. Previous studies have shown that steroid eye drops are effective in some, but not all patients. Furthermore, steroid eye drops are not appropriate for certain patients. In a study involving 18 patients with leukemia, steroid eye drops were compared with a formulation approximating the composition of natural tears. All 18 patients had leukemia which either relapsed or did not respond to initial chemotherapy and they were schedules to receive ara-C treatment. Nine patients were given the artificial tears and nine patients were given eye drops containing prednisolone, a glucocorticoid drug. The eye drops were administered every four hours, starting before the first dose of ara-C and continuing for two days after the chemotherapeutic treatment had ended. Mild or moderate eye reactions were experienced by three of the patients using the artificial tears and by five of the patients treated with the steroid eye drops. These results indicate that artificial tears are just as effective as steroid eye drops. It seems likely, therefore, that the effect that was previously observed with the steroid eye drops had nothing to do with the anti-inflammatory effects of steroids. Rather, it seems now that the eye drops simply dilute the cytosine arabinoside which has found its way onto the surface of the eye and that artificial tears accomplish this dilution just as well. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1991

41. Abstract CT088: Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non-small cell lung cancer (NSCLC)

Author

Lovly, Christine M., primary, Infante, Jeffrey R., additional, Blumenschein, George R., additional, Reckamp, Karen, additional, Wakelee, Heather, additional, Carter, Corey A., additional, Waqar, Saiama N., additional, Neal, Joel, additional, Gockerman, Jon P., additional, Dukart, Gary, additional, Harrow, Kimberly, additional, Liang, Chris, additional, Gibbons, James J., additional, and Horn, Leora, additional

Published
2016
Full Text
View/download PDF

42. Plasma genotyping of patients enrolled on the expansion phase I/II trial of X-396 in patients (pts) with ALK+ non-small cell lung cancer (NSCLC).

Author

Horn, Leora, primary, Wakelee, Heather A., additional, Reckamp, Karen L., additional, Blumenschein, George R., additional, Infante, Jeffrey R., additional, Carter, Corey Allan, additional, Waqar, Saiama Naheed, additional, Neal, Joel W., additional, Gockerman, Jon P, additional, Harrow, Kimberly, additional, Dukart, Gary, additional, Liang, Chris, additional, Gibbons, James J., additional, Hernandez, Jennifer, additional, Newman-Eerkes, Tara, additional, Lim, Lee, additional, and Lovly, Christine Marie, additional

Published
2016
Full Text
View/download PDF

45. Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial andin vitrostudies

Author

Friedman, Daphne R., primary, Lanasa, Mark C., additional, Davis, Patricia H., additional, Allgood, Sallie D., additional, Matta, Karen M., additional, Brander, Danielle M., additional, Chen, Youwei, additional, Davis, Evan D., additional, Volkheimer, Alicia D., additional, Moore, Joseph O., additional, Gockerman, Jon P., additional, Sportelli, Peter, additional, and Weinberg, J. Brice, additional

Published
2013
Full Text
View/download PDF

46. Non-Hodgkin’s Lymphomas, Version 1.2013

Author

Zelenetz, Andrew D., primary, Wierda, William G., additional, Abramson, Jeremy S., additional, Advani, Ranjana H., additional, Andreadis, C. Babis, additional, Bartlett, Nancy, additional, Bellam, Naresh, additional, Byrd, John C., additional, Czuczman, Myron S., additional, Fayad, Luis E., additional, Glenn, Martha J., additional, Gockerman, Jon P., additional, Gordon, Leo I., additional, Harris, Nancy Lee, additional, Hoppe, Richard T., additional, Horwitz, Steven M., additional, Kelsey, Christopher R., additional, Kim, Youn H., additional, Krivacic, Susan, additional, LaCasce, Ann S., additional, Nademanee, Auayporn, additional, Porcu, Pierluigi, additional, Press, Oliver, additional, Pro, Barbara, additional, Reddy, Nishitha, additional, Sokol, Lubomir, additional, Swinnen, Lode, additional, Tsien, Christina, additional, Vose, Julie M., additional, Yahalom, Joachim, additional, Zafar, Nadeem, additional, Dwyer, Mary A., additional, and Naganuma, Maoko, additional

Published
2013
Full Text
View/download PDF

47. A Phase I Study of Arsenic Trioxide (Trisenox), Ascorbic Acid, and Bortezomib (Velcade) Combination Therapy in Patients With Relapsed/Refractory Multiple Myeloma

Author

Held, Lauren A., primary, Rizzieri, David, additional, Long, Gwynn D., additional, Gockerman, Jon P., additional, Diehl, Louis F., additional, Castro, Carlos M. de, additional, Moore, Joseph O., additional, Horwitz, Mitchell E., additional, Chao, Nelson J., additional, and Gasparetto, Cristina, additional

Published
2013
Full Text
View/download PDF

49. Non-Hodgkin’s Lymphomas, Version 3.2012

Author

Zelenetz, Andrew D., primary, Wierda, William G., additional, Abramson, Jeremy S., additional, Advani, Ranjana H., additional, Andreadis, C. Babis, additional, Bartlett, Nancy, additional, Bellam, Naresh, additional, Byrd, John C., additional, Czuczman, Myron S., additional, Fayad, Luis, additional, Glenn, Martha J., additional, Gockerman, Jon P., additional, Gordon, Leo I., additional, Harris, Nancy Lee, additional, Hoppe, Richard T., additional, Horwitz, Steven M., additional, Kelsey, Christopher R., additional, Kim, Youn H., additional, Krivacic, Susan, additional, LaCasce, Ann S., additional, Nademanee, Auayporn, additional, Porcu, Pierluigi, additional, Press, Oliver, additional, Pro, Barbara, additional, Reddy, Nishitha, additional, Sokol, Lubomir, additional, Swinnen, Lode, additional, Tsien, Christina, additional, Vose, Julie M., additional, Yahalom, Joachim, additional, Zafar, Nadeem, additional, Naganuma, Maoko, additional, and Dwyer, Mary A., additional

Published
2012
Full Text
View/download PDF

50. Pilot Study of Sorafenib for Myelodysplastic Syndrome

Author

Rao, Arati, primary, Rizzieri, David A., additional, Vanegas, Eduardo, additional, Moore, Joseph O., additional, Gockerman, Jon P., additional, Diehl, Louis F., additional, Adams, Donna, additional, Warzecho, Julie, additional, and Decastro, Carlos, additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results